FIG. 3.

Reduction in tumor burden and survival benefit for patients receiving neoadjuvant immunotherapy. a A waterfall plot depicting the maximum percentage change in tumor size with neoadjuvant immunotherapy versus the pretreatment baseline for each patient. The x-axis represents the individual patients in the study. b Spider plots depicting percentage change in tumor burden per RECIST version 1.1 during each determined assessment period. Each line represents an individual patient. c Kaplan–Meier estimates of relapse-free survival (RFS) among patients receiving neoadjuvant immunotherapy. The median RFS was not reached. d Kaplan–Meier estimates of overall survival among patients receiving neoadjuvant immunotherapy compared with the adjuvant cohort. The median overall survival was not reached